Card image cap
Phase 2,3 trial data of India’s first mRNA Covid vaccine submitted

Pune-based Gennova Biopharmaceuticals has submitted the phase-II and phase-III trials data of India’s first mRNA Covid vaccine to the drug regulator– Drugs Controller General of India (DCGI)– on Friday. ICMR had earlier announced that this vaccine is going to be useful in future for the treatments of not only Covid but  other diseases as well. Gennova has also developed an Omicron-specific vaccine, which will be tested on humans for efficacy and immunogenicity soon.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment